Litcius/Paper detail

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K Abou-Alfa, Anthony B El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro

2021The Lancet Oncology1,097 citationsDOI

Topics & Concepts

NivolumabMedicineSorafenibHepatocellular carcinomaInternal medicineOncologyCancer researchPhase (matter)CarcinomaPhases of clinical researchRenal cell carcinomaClinical trialImmunotherapyHepatocellular cancerHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersLiver physiology and pathology
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial | Litcius